1. Feigin VL, Norrving B, Mensah GA. Global burden of stroke.
Circ Res 2017;120:439-448.
2. Wang W, Wang D, Liu H, Sun H, Jiang B, Ru X, et al. Trend of declining stroke mortality in China: reasons and analysis.
Stroke Vasc Neurol 2017;2:132-139.
4. Shahar E, Chambless LE, Rosamond WD, Boland LL, Ballantyne CM, McGovern PG, et al. Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study.
Stroke 2003;34:623-631.
5. Tirschwell DL, Smith NL, Heckbert SR, Lemaitre RN, Longstreth WT Jr, Psaty BM. Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups.
Neurology 2004;63:1868-1875.
6. Wang X, Dong Y, Qi X, Huang C, Hou L. Cholesterol levels and risk of hemorrhagic stroke: a systematic review and metaanalysis.
Stroke 2013;44:1833-1839.
7. Xie L, Wu W, Chen J, Tu J, Zhou J, Qi X, et al. Cholesterol levels and hemorrhagic stroke risk in East Asian versus non-East Asian populations: a systematic review and meta-analysis.
Neurologist 2017;22:107-115.
8. Laloux P, Galanti L, Jamart J. Lipids in ischemic stroke subtypes.
Acta Neurol Belg 2004;104:13-19.
9. Hindy G, Engström G, Larsson SC, Traylor M, Markus HS, Melander O, et al. Role of blood lipids in the development of ischemic stroke and its subtypes: a Mendelian randomization study.
Stroke 2018;49:820-827.
10. Glasser SP, Mosher A, Howard G, Banach M. What is the association of lipid levels and incident stroke?
Int J Cardiol 2016;220:890-894.
11. Pikula A, Beiser AS, Wang J, Himali JJ, Kelly-Hayes M, Kase CS, et al. Lipid and lipoprotein measurements and the risk of ischemic vascular events: Framingham Study.
Neurology 2015;84:472-479.
12. Bangalore S, Breazna A, DeMicco DA, Wun CC, Messerli FH; TNT Steering Committee and Investigators. Visit-to-visit lowdensity lipoprotein cholesterol variability and risk of cardiovascular outcomes: insights from the TNT trial.
J Am Coll Cardiol 2015;65:1539-1548.
13. Waters DD, Bangalore S, Fayyad R, DeMicco DA, Laskey R, Melamed S, et al. Visit-to-visit variability of lipid measurements as predictors of cardiovascular events.
J Clin Lipidol 2018;12:356-366.
14. Boey E, Gay GM, Poh KK, Yeo TC, Tan HC, Lee CH. Visit-to-visit variability in LDL- and HDL-cholesterol is associated with adverse events after ST-segment elevation myocardial infarction: a 5-year follow-up study.
Atherosclerosis 2016;244:86-92.
15. Smit RA, Trompet S, Sabayan B, le Cessie S, van der Grond J, van Buchem MA, et al. Higher visit-to-visit low-density lipoprotein cholesterol variability is associated with lower cognitive performance, lower cerebral blood flow, and greater white matter hyperintensity load in older subjects.
Circulation 2016;134:212-221.
16. Clark D 3rd, Nicholls SJ, St John J, Elshazly MB, Kapadia SR, Tuzcu EM, et al. Visit-to-visit cholesterol variability correlates with coronary atheroma progression and clinical outcomes.
Eur Heart J 2018;39:2551-2558.
18. Kim MK, Han K, Park YM, Kwon HS, Kang G, Yoon KH, et al. Associations of variability in blood pressure, glucose and cholesterol concentrations, and body mass index with mortality and cardiovascular outcomes in the general population.
Circulation 2018;138:2627-2637.
19. Wang A, Chen S, Wang C, Zhou Y, Wu Y, Xing A, et al. Resting heart rate and risk of cardiovascular diseases and allcause death: the Kailuan study.
PLoS One 2014;9:e110985.
20. Xu Y, Li H, Wang A, Su Z, Yang G, Luo Y, et al. Association between the metabolically healthy obese phenotype and the risk of myocardial infarction: results from the Kailuan study.
Eur J Endocrinol 2018;179:343-352.
21. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate.
Ann Intern Med 2009;150:604-612.
22. Stroke: 1989. Recommendations on stroke prevention, diagnosis, and therapy. Report of the WHO Task Force on Stroke and other Cerebrovascular Disorders.
Stroke 1989;20:1407-1431.
23. Vidal-Petiot E, Stebbins A, Chiswell K, Ardissino D, Aylward PE, Cannon CP, et al. Visit-to-visit variability of blood pressure and cardiovascular outcomes in patients with stable coronary heart disease. Insights from the STABILITY trial.
Eur Heart J 2017;38:2813-2822.
24. Wang A, Liu X, Xu J, Han X, Su Z, Chen S, et al. Visit-to-visit variability of fasting plasma glucose and the risk of cardiovascular disease and all-cause mortality in the general population.
J Am Heart Assoc 2017;6:e006757.
25. Bangalore S, Fayyad R, Laskey R, DeMicco DA, Messerli FH, Waters DD. Body-weight fluctuations and outcomes in coronary disease.
N Engl J Med 2017;376:1332-1340.
26. Lim YM, Yang PS, Jang E, Yu HT, Kim TH, Uhm JS, et al. Body mass index variability and long-term risk of new-onset atrial fibrillation in the general population: a Korean nationwide cohort study.
Mayo Clin Proc 2019;94:225-235.
28. Kim MK, Han K, Koh ES, Kim HS, Kwon HS, Park YM, et al. Variability in total cholesterol is associated with the risk of end-stage renal disease: a nationwide population-based study.
Arterioscler Thromb Vasc Biol 2017;37:1963-1970.
29. Yaghi S, Elkind MS. Lipids and cerebrovascular disease: research and practice.
Stroke 2015;46:3322-3328.
31. Lee JS, Chang PY, Zhang Y, Kizer JR, Best LG, Howard BV. Triglyceride and HDL-C dyslipidemia and risks of coronary heart disease and ischemic stroke by glycemic dysregulation status: the Strong Heart Study.
Diabetes Care 2017;40:529-537.
32. Bardini G, Innocenti M, Rotella CM, Giannini S, Mannucci E. Variability of triglyceride levels and incidence of microalbuminuria in type 2 diabetes.
J Clin Lipidol 2016;10:109-115.
33. Wang A, Dai L, Su Z, Chen S, Li J, Wu S, et al. Proteinuria and risk of stroke in patients with hypertension: the Kailuan cohort study.
J Clin Hypertens (Greenwich) 2018;20:765-774.
34. Wang A, Liu X, Su Z, Chen S, Zhang N, Wu S, et al. Two-year changes in proteinuria and the risk of stroke in the Chinese population: a prospective cohort study.
J Am Heart Assoc 2017;6:e006271.